SEC Form 4 · accession 0001209191-18-050553
Karyopharm Therapeutics Inc. · KPTI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Brett Primiano
Officer — EVP, CBO, GC & Secretary
Period of report
Sep 10, 2018
Accepted (ET)
Sep 11, 2018 · 6:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001503802
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 10, 2018 | M | 5,000 | $6.54 | A | 7,881 | D | |
| Common Stock | Sep 10, 2018 | M | 5,000 | $10.39 | A | 12,881 | D | |
| Common StockF2 | Sep 10, 2018 | S | 10,000 | $18.9046 | D | 2,881 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $6.54 | Sep 10, 2018 | M | 5,000 | D | — | Jan 14, 2026 | Common Stock | 5,000 | 18,000 | D |
| Stock Option (right to buy)F4 | $10.39 | Sep 10, 2018 | M | 5,000 | D | — | Jan 19, 2027 | Common Stock | 5,000 | 113,000 | D |
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $18.27 to $19.08, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 15, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.
- F4This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.